At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
ofatumumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Ofatumumab (CALGB IND #) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
In Brief
A Phase 2 clinical trial evaluating ofatumumab for Lymphoma. Completed, enrolled 51 participants across 48 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This randomized phase II trial is studying ofatumumab to see how well it works in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartAug 2011
Primary CompletionMar 2015
Study CompletionOct 2020
TodayJul 2026
First PostedAug 27, 2010
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2015
Study CompletionOct 15, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.8 years ago
Interventions
ofatumumabbiological
Given IV